SI3045474T1 - Terapevtska sredstva za zdravljenje bolezni povezane z neželeno proliferacijo celic - Google Patents

Terapevtska sredstva za zdravljenje bolezni povezane z neželeno proliferacijo celic

Info

Publication number
SI3045474T1
SI3045474T1 SI201032059T SI201032059T SI3045474T1 SI 3045474 T1 SI3045474 T1 SI 3045474T1 SI 201032059 T SI201032059 T SI 201032059T SI 201032059 T SI201032059 T SI 201032059T SI 3045474 T1 SI3045474 T1 SI 3045474T1
Authority
SI
Slovenia
Prior art keywords
treatment
therapeutic agents
cell proliferation
diseases associated
unwanted cell
Prior art date
Application number
SI201032059T
Other languages
English (en)
Slovenian (sl)
Inventor
Suarez Joan Seoane
Prieto Silvia Penuelas
Torres Jose Baselga
Original Assignee
Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats
Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron
Fundacio Privada Institut De Recerca Hospital Universitari Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron, Fundacio Privada Institut De Recerca Hospital Universitari Vall Hebron filed Critical Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats
Publication of SI3045474T1 publication Critical patent/SI3045474T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
SI201032059T 2009-04-03 2010-04-06 Terapevtska sredstva za zdravljenje bolezni povezane z neželeno proliferacijo celic SI3045474T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP16155009.0A EP3045474B1 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Publications (1)

Publication Number Publication Date
SI3045474T1 true SI3045474T1 (sl) 2021-07-30

Family

ID=42342718

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201032059T SI3045474T1 (sl) 2009-04-03 2010-04-06 Terapevtska sredstva za zdravljenje bolezni povezane z neželeno proliferacijo celic

Country Status (24)

Country Link
US (4) US10100112B2 (enExample)
EP (2) EP3045474B1 (enExample)
JP (5) JP6207836B2 (enExample)
KR (6) KR20120100703A (enExample)
CN (2) CN107964043A (enExample)
AU (1) AU2010233791B2 (enExample)
BR (1) BRPI1015369A2 (enExample)
CA (1) CA2757680C (enExample)
CY (1) CY1124148T1 (enExample)
DK (1) DK3045474T3 (enExample)
EA (1) EA201101450A1 (enExample)
ES (2) ES2363358B1 (enExample)
HR (1) HRP20210352T1 (enExample)
HU (1) HUE054196T2 (enExample)
IL (1) IL215467A (enExample)
LT (1) LT3045474T (enExample)
MX (1) MX336903B (enExample)
PL (1) PL3045474T3 (enExample)
PT (1) PT3045474T (enExample)
SG (2) SG10202010568RA (enExample)
SI (1) SI3045474T1 (enExample)
SM (1) SMT202100153T1 (enExample)
WO (1) WO2010115868A2 (enExample)
ZA (1) ZA201107215B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565172A (en) * 2005-07-19 2012-12-21 Stemgen S P A Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
CA2941703A1 (en) * 2014-03-11 2015-09-17 Godavari Biorefineries Limited Cancer stem cell targeting compounds
KR102503476B1 (ko) * 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
JP2017527582A (ja) * 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
WO2016154203A1 (en) 2015-03-23 2016-09-29 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
SG11202011170YA (en) * 2018-05-14 2020-12-30 Medimmune Ltd Antibodies against lif and dosage forms thereof
EP3806899A2 (en) * 2018-06-18 2021-04-21 MedImmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
KR20210024007A (ko) * 2018-06-18 2021-03-04 메디뮨 리미티드 암이 있는 개체에서 항-lif 항체 치료에 대한 반응을 개선하기 위한 방법
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
WO2020213665A1 (ja) * 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies
CN120507517B (zh) * 2025-05-21 2026-04-10 浙江省肿瘤医院 用于评估宫颈癌鳞癌和腺癌特异性的预后分子标记物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
AU632993B2 (en) 1987-12-15 1993-01-21 Gene Shears Pty. Limited Ribozymes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003085093A2 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP1576131A4 (en) * 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040248158A1 (en) * 2003-01-28 2004-12-09 Loughran Thomas P Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
CA2734172A1 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Diagnostics and treatments for vegf-independent tumors
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Also Published As

Publication number Publication date
US20120114671A1 (en) 2012-05-10
MX2011010425A (es) 2012-03-06
CN107964043A (zh) 2018-04-27
SG175032A1 (en) 2011-11-28
KR102373754B1 (ko) 2022-03-15
ES2363358A1 (es) 2011-08-01
JP2022031742A (ja) 2022-02-22
IL215467A (en) 2016-06-30
MX336903B (es) 2016-02-04
HUE054196T2 (hu) 2021-08-30
JP2020090522A (ja) 2020-06-11
CA2757680A1 (en) 2010-10-14
EP3045474A2 (en) 2016-07-20
EA201101450A1 (ru) 2012-04-30
JP2016040255A (ja) 2016-03-24
WO2010115868A3 (en) 2011-02-03
SMT202100153T1 (it) 2021-05-07
JP2019006784A (ja) 2019-01-17
KR20200078668A (ko) 2020-07-01
CY1124148T1 (el) 2022-05-27
PT3045474T (pt) 2021-03-22
BRPI1015369A2 (pt) 2021-06-29
EP3045474B1 (en) 2021-01-13
AU2010233791A1 (en) 2011-11-03
AU2010233791B2 (en) 2016-01-21
US10100112B2 (en) 2018-10-16
KR20190093691A (ko) 2019-08-09
KR20120100703A (ko) 2012-09-12
PL3045474T3 (pl) 2021-08-09
LT3045474T (lt) 2021-05-10
KR20180079470A (ko) 2018-07-10
US20200385455A1 (en) 2020-12-10
WO2010115868A2 (en) 2010-10-14
EP3045474A3 (en) 2016-09-28
ES2864639T3 (es) 2021-10-14
US11999782B2 (en) 2024-06-04
HRP20210352T1 (hr) 2021-05-28
JP2012522756A (ja) 2012-09-27
IL215467A0 (en) 2011-12-29
JP7197665B2 (ja) 2022-12-27
DK3045474T3 (da) 2021-03-22
EP2414394A2 (en) 2012-02-08
CN102574918A (zh) 2012-07-11
US20190211095A1 (en) 2019-07-11
SG10202010568RA (en) 2020-11-27
ES2363358B1 (es) 2012-06-21
KR20170121319A (ko) 2017-11-01
KR20220035978A (ko) 2022-03-22
CA2757680C (en) 2021-11-02
ZA201107215B (en) 2012-12-27
US20240400667A1 (en) 2024-12-05
JP6207836B2 (ja) 2017-10-04

Similar Documents

Publication Publication Date Title
HUE054196T2 (hu) Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
CY2014006I2 (el) Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf
BRPI1012129A2 (pt) enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
IL200368A0 (en) Treatment of diseases characterized by inflammation
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
HUE072183T2 (hu) Génterápia neurodegeneratív betegségekre
PL2435825T3 (pl) Sposoby leczenia chorób
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
BRPI0821779A2 (pt) tratamento terapêutico de câncer
EP2613786A4 (en) TREATMENT OF DISEASES
ZA201301601B (en) Treatment of diseases
HRP20180575T1 (hr) Cervikalni jastuk za liječenje bolesti vratne kralježnice
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
EP2608808A4 (en) TREATMENT OF NEOPLASIS DISEASES
ZA200905364B (en) Treatment of diseases characterized by inflammation
HUE033690T2 (hu) Terápiás szer hangulatzavarokra
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
BRPI0923377A2 (pt) Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos
IL223175A0 (en) Tamarind seed polysaccharide for use in the treatment of inflammatory diseases
EP2554163A4 (en) THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES
PL2467140T3 (pl) Lapatynib do leczenia raka